Significant Ownership of Bellevue Group AG

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for Bellevue Group AG focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Stefano Montalbano - Stefano Montalbano/ Chief Financial Officer
Manager location
Zurich

Follow Filing Activity

Follow Bellevue Group AG and return when a new Schedule 13D/G filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Significant Ownership of Bellevue Group AG

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
JBIO Jade Biosciences, Inc. Common Stock 6.8% $46,307,688 3,341,103 Bellevue Group AG 16 Dec 2025
VRDN Viridian Therapeutics, Inc. Common Stock 6.6% $93,493,402 6,726,144 Bellevue Group AG 31 Mar 2026
IMCR Immunocore Holdings plc Ordinary shares 5.6% $101,607,853 2,796,803 Bellevue Group AG 20 Aug 2025
CLDX Celldex Therapeutics, Inc. Common Stock 1.5% $37,512,000 -$75,576,333 1,200,000 -67% Bellevue Group AG 31 Mar 2026
MGNX MacroGenics, Inc. Common Stock 0% $0 -$13,901,948 0 -100% Bellevue Group AG 05 Dec 2025
AGIO Agios Pharmaceuticals, Inc. Common Stock 0% $0 -$142,398,726 0 -100% Bellevue Group AG 19 Nov 2025

Schedules 13D/G Reported by Bellevue Group AG:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .